53 . NUTINI MT. Pharmacovigilance Hevac B Pasteur. J. Am. Med. Assoc. (suppl hors série) 1987: 5-7.
76 . ANDRÉ FE. Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine. Vaccine 1990; 8 : 74-8..
77 . MACMAHON BJ, HELMINIAK C, WAINWRIGHT RB, BULKOW L, TRIMBLE BA, WAINWRIGHT K. Frequency of adverse reactions to hepatitis B vaccine in 43618 persons. Am. J. Med. 1992; 92: 254-6.
94 . DE SILVA L, ROGERS M. Hepatitis B vaccine: urticarial reaction. Med. J. Austr. 1985; 143: 323-4.
95 . GOLDWATER PN Hypersensitivity to intradermal hepatitis B vaccine. Lancet 1984; 17:1156.
96 . BRIGHTMAN CAJ, SCADDING GK, DUMBRECK TA, LATCHMAN Y; BROSTOFF J. yeast-derived hepatitis B vaccine and yeast sensitivity. Lancet 1989; 333: 903.
97 . PIERCHALLA P, PETRI H, RUPING K. Urticaria after HB-Vax injection due to hypersensitivity to thiomersal (merthiolate). Allergologie 1987; 10: 97-9.
98 . HUDSON Pg, NEWKIRK M, GERVAIS F, SHUSTER J. Adverse reaction to the recombinant hepatitis B vaccine. J. Allergy Clin. Inmunol. 1991; 88: 821-2.
99 . LOHIYA G. Asthma and urticaria after hepatitis B vaccination. The Western J. Med. 1987; 147: 341.
100. SEAL D, FICKER L, WRIGHT P, ANDREWS V. The case against thiomersal. Lancet 1991; 338: 315-6.
101. TOSTI A, MELINO M, BARDAZZI F. Systemic reactions due to thirmerosal. Contact Dermatitis 1986; 15: 187-8.
102. KURITSKY J. Apparent reactions to thimerosal. Division of epidemiology and surveillance of the FDA 1987:12 juin.
103. KIRKLAND LR. Ocular sensitivity to thimerosal : a problem with hepatitis B vaccine? South Med. J. 1990; 83: 497-9.
104. BOXALL EH, PLESTER CL, WEBBER SR. Vaccine hypersensitivity or coincidental virus infection. Vaccine 1989; 7:77.
135 . MORRIS CA, OLIVER PR, REYNOLDS F, SELKON JB. Intradermal hepatitis B immunization with yeast-derived vaccine: serological response by sex and age. Epidemiol. Infect. 1989; 103: 387-94.
136. Morbidity and mortality weekly report. Safety of hepatitis B vaccine. J. Am. Med. Assoc. 1983; 249:1812.